Get the Stockscreener App
8.77
0.69%
0.06
Pre-market:
8.79
0.02
+0.23%
Immunitybio Inc stock is traded at $8.77, with a volume of 15.72M.
It is up +0.69% in the last 24 hours and up +16.62% over the past month.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
See More
Previous Close:
$8.71
Open:
$8.36
24h Volume:
15.72M
Relative Volume:
1.07
Market Cap:
$9.19B
Revenue:
$140.98M
Net Income/Loss:
$-854.60M
P/E Ratio:
-10.27
EPS:
-0.854
Net Cash Flow:
$-299.31M
1W Performance:
+21.47%
1M Performance:
+16.62%
6M Performance:
+329.90%
1Y Performance:
+224.81%
1-Day Range:
$8.3335
$9.08
1-Week Range:
$7.00
$9.08
52-Week Range:
$1.95
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
8.77 | 9.12B | 140.98M | -854.60M | -299.31M | -0.854 |
VRTX
Vertex Pharmaceuticals Inc
|
499.65 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
631.81 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
912.46 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
192.62 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.52 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Resumed | BTIG Research | Buy |
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
View All
Immunitybio Inc Stock (IBRX) Latest News
IBRX Stock Eyes Best Week Since February: Founder Highlights New Anktiva-NK Cell Therapy Study - Stocktwits
IBRX Stock At 3-Month High: Retail Bulls Eye July Catalysts Around Anktiva Saudi Expansion, Q2 Sales - Stocktwits
[144] ImmunityBio, Inc. SEC Filing - Stock Titan
ImmunityBio, Inc.(NasdaqGS: IBRX) dropped from Russell 2000 Value Benchmark - marketscreener.com
IBRX Stock Is Back: Anktiva Now Targets Severe Pneumonia After Clearing Key Checkpoint In Bladder Cancer Trial - Stocktwits
ImmunityBio (IBRX) Moves 11.8% Higher: Will This Strength Last? - Yahoo Finance
IBRX Stock Climbs Overnight: ImmunityBio Declares ‘All Systems Go’ For Dunkirk Anktiva Manufacturing Push - Stocktwits
Enterprise value to revenue forward of ImmunityBio, Inc. – NASDAQ:IBRX - TradingView
SLS, IBRX Eye Green Month As Biotech ETF Gains Steam: Analyst Sees ‘Continued Opportunities’ In Immuno-Oncology - Stocktwits
IBRX Stock Lights Up: Retail Cheers Calls For Trump To ‘Pull The Plug’ On FDA Chief Marty Makary Amid Anktiva Row - Stocktwits
Enterprise value to revenue forward of ImmunityBio Inc – TRADEGATE:26CA - TradingView
IBRX Stock Still A Buy After Worst Day In Over A Year? Why This Analyst Is Shrugging Off FDA Warning Letter - Stocktwits
IBRX Stock In Spotlight: ImmunityBio To Unveil Fresh Anktiva And BCG Data Next Week - Stocktwits
ImmunityBio, Inc. (IBRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
IBRX Stock In Spotlight As FDA Scrutiny Prompts ImmunityBio To Withdraw Content, Tighten Oversight - Stocktwits
ImmunityBio, Inc. (IBRX) Investigation: Bronstein, Gewirtz & Gros - The National Law Review
2026-06-28 | ImmunityBio, Inc. (IBRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | NDAQ:IBRX | Press Release - Stockhouse
IBRX Stock Enters Heavy Catalyst Phase: Traders Brace For Key Anktiva Decision Amid Trump’s FDA Turmoil - Stocktwits
IBRX Stock Jumps After-Hours: Bulls Cheer ‘Unstoppable’ Global Expansion Amid US Regulatory Heat For Anktiva - Stocktwits
ImmunityBio Founder Reaffirms Grip As Stock Plunges In Worst Selloff Since 2024 After Massive Rally - Stocktwits
ImmunityBio (NASDAQ:IBRX) trades after post-Russell spike with 46% more volume - TechStock²
Enterprise value to EBITDA forward of ImmunityBio, Inc. – NASDAQ:IBRX - TradingView
Form 4 Immunitybio Inc For: 26 June By Investing.com - Investing.com Canada
symbol__ Stock Quote Price and Forecast - CNN
ImmunityBio Founder Pushes Back After FDA Warning Letter Over Anktiva Claims — Says Ad 'Never Aired At All' - Stocktwits
Enterprise value to EBIT forward of ImmunityBio Inc – SWB:26CA - TradingView
Director Barry Simon Sells 25,000 Shares of ImmunityBio Inc (IBR - GuruFocus
ImmunityBio (NASDAQ: IBRX) director sells 25,000 shares under 10b5-1 plan - Stock Titan
ImmunityBio director Simon Barry J. sells $196,907 of common stock - Investing.com
ImmunityBio director Simon Barry J. sells $196,907 of common stock By Investing.com - Investing.com Nigeria
Price to sales forward of ImmunityBio, Inc. – NASDAQ:IBRX - TradingView
ImmunityBio (NASDAQ:IBRX) rises as Russell index rebalancing and high multiple draw buyers - TechStock²
Price to earnings forward of ImmunityBio Inc – SWB:26CA - TradingView
IBRX Stock Climbs As ANKTIVA Data Spotlight Draws Traders - StocksToTrade
ImmunityBio Confirms Trial Strength For Anktiva In Bladder Cancer - Stocktwits
Price to sales forward of ImmunityBio Inc – SWB:26CA - TradingView
IBRX Stock Ignites Retail Frenzy Ahead Of Founder’s Prime-Time TV Blitz — Traders Bets On Saudi Funding And Trump Tailwinds - Stocktwits
IBRX Stock Set To Snap 2 Days Of Losses? Anktiva Back In Focus Ahead Of COVID-Cancer Link Data - Stocktwits
ImmunityBio, Inc. (IMMP) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
IBRX Stock Price Prediction 2025-2026 | Immunitybio Inc Forecast - 24/7 Wall St.
ImmunityBio reports progress on bladder cancer filing, shares trade quietly on NASDAQ - Ad-hoc-news.de
Immunitybio Inc (IBRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
IBRX Founder’s ‘Congrats’ To GSK Sparks Debate After FDA Fast Drug Approvals — Retail Slams Big Pharma Bias Over Anktiva - Stocktwits
Price to book forward of ImmunityBio, Inc. – NASDAQ:IBRX - TradingView
Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc. (IMMP) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating ImmunityBio, Inc. (IMMP) And Encourages Shareholders to Connect - ACCESS Newswire
Jim Cramer Says “Let ImmunityBio Be Your Speculation” to a Caller - Insider Monkey
IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead? - Stocktwits
IBRX Stock Rises Premarket: Anktiva Moves Into Pre-Surgery Pancreatic Cancer Combo Trial With Bristol Myers Drug - Stocktwits
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):